Our editorial published in this months JIM - @liverepi.bsky.social & colleagues identify MASLD in 18.1% of 28,000 middle-aged Swedish adults, define MASLD risk factors that translate into actionable advice for patients and identify risk with any alcohol use and possible deleterious effects of coffee

Delighted to share the evolution of @torchuk.bsky.social and our lessons learnt as a road map 🗺️ 🏥 Such a pleasure to work with talented colleagues across the UK to shape this and prime our project pipeline to improve outcomes in liver disease doi.org/10.1136/flga... #liversky #gastrosky #EVADE

Great article from Lazarus et al on the parallels today in the fight against MASLD with previous lessons learned from viral hepatitis

ICYMI: New online! Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease

Our editorial in Hepatology about the FMO (fibrotic/ at-risk MASH in obesity) score. Developed to identify At-risk MASH. Validated in 4 external cohort. It uses ALT, AST, triglycerides and HDL and is able to rule-our At-risk MASH with a NPV of 0.97 and predicts LRE. journals.lww.com/hep/citation...

Traction building nicely across the 🇬🇧 Any help with spreading the word and getting hospital sites involved in your regions would be greatly appreciated 🙏🏼 We are folding in patient trajectory as a novel angle - should be interesting! #liversky

Our paper published today in Frontline Gastro 18 months after introducing a decentralised Fibroscan service: ⇒Patient: 33 564 km and 16.1 days of travel saved. ⇒Environmental: 4929.4 kgCO2 of CO2 saved. ⇒Hospital services: 167 hospital appointments saved (=£43,587). fg.bmj.com/content/flga...

Fantastic to see the updated BSG/BASL decompensated cirrhosis admission bundle in print at FG - practical guidance to improve care in the first 24 hours as well as implementation strategy - congrats Stuart McPherson for driving this! #livertwitter fg.bmj.com/content/earl...